Home > Drug Search >
  • Targets: NAD(P)H dehydrogenase
  •   > 
Drug Filter
Status:
Approved (4) Phase Ⅲ (2) Phase Ⅱ (7) Phase Ⅰ (5) IND Filing (1)
Clinical Stage:
Pending (1) Active (8) Discontinued (6)
Company:
Sumitomo Dainippon (1) Edison pharmaceuticals (1) Ipsen (1) Japan Tobacco (1) Johnson & Johnson (2) Kadmon (1) Lantheus Medical Imaging (1) Ligand (1) Merck Serono (1) Novartis (1) Sanofi (1) Unknown (1) Biomeasure (1) Italfarmaco (1) MEI Pharma (1) Novogen (1) Aileron Therapeutics (1) Theratechnologies (1) Global Blood Therapeutics (1) Beijing Collab Pharma (1) Aegerion (2) Baxter (1) Bristol-Myers Squibb (1)
Indication:
Amyotrophic lateral sclerosis (ALS) (1) Anemia (1) Coronary artery disease (CAD) (1) Gastrointestinal haemorrhage (1) Growth hormone deficit (1) Hypercholesterolemia (2) Hyperlipidemia (3) Hypertriglyceridemia (1) Somatotropin deficiency (2) Obesity (1) Parkinson's disease (PD) (1) Solid tumours (1) Type 2 diabetes (3) Venous thromboembolism (VTE) (1) Homozygous familial hypercholesterolemia (1) Sickle cell disease (1) Acromegaly (2) Dwarfism (1) Turner syndrome (1) Skin ulcer (1) Neuroendocrine tumors (NET) (1) Thrombosis (1) Lipodystrophy (1)
Others:
Sort: Aprv. Year Alphabetical Prev Next
First Prev 1 Next Last GO
Recently Viewed Drugs:
Insert title here
Feed-Back To Top
ICP Permit 14047345| Beijing PSB Hai Dian Record 11010802017043 |(京)-经营性-2015-0023(互联网药品信息服务资格证书)
Insert title here
Feed-Back To Top